Quetiapine Extended Release

76,608 adverse event reports submitted to the FDA (2001–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Quetiapine Extended Release in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Quetiapine Extended Release adverse event reports by reporter sex
SexReports
Female39,882
Male29,616
Unknown193

By Age Group

View age group data as a table
Quetiapine Extended Release adverse event reports by reporter age group
Age groupReports
0-173,825
18-3412,419
35-4914,618
50-6414,529
65-747,471
75+8,189

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Quetiapine Extended Release. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Quetiapine Extended Release adverse event reports by reported outcome
OutcomeReports
Other Serious43,413
Hospitalization34,839
Death15,443
Life-Threatening8,285
Non-Serious5,097
Disability3,254

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Quetiapine Extended Release. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Quetiapine Extended Release adverse event reports by year
YearReports
20011
2004211
2005149
2006133
200784
2008256
2009246
2010831
20111,004
20121,214
20131,556
20142,285
20152,912
20163,047
20174,900
20186,348
20197,080
20207,516
20217,050
20226,812
20237,220
20247,218
20256,764
2026 (partial)1,771

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Quetiapine Extended Release

In FDA adverse event reports that mention Quetiapine Extended Release, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026